• Early Pheromones and Adult Neurodegeneration in C. elegans

  2026-10-09

  Peng et al. show that early exposure to the C. elegans pheromones ascr#3 and ascr#10 can remodel neural development and accelerate neurodegeneration later in life through coordinated chemosensory, neuropeptide, glutamatergic, insulin-like, and autophagy-related signaling. The study provides a mechanistic framework for understanding how developmental chemical environments can influence adult proteostasis, while its conclusions remain bounded by the nematode model and the specific signaling circuitry examined.

• Tetracycline Hydrochloride: Mechanism and Evidence

  2026-10-09

  Tetracycline Hydrochloride is a bacteriostatic antibiotic whose ribosome-directed activity offers a useful model for interpreting bacterial translation and antimicrobial data. This evidence-focused article distinguishes its mechanism from the rapid ROS-based cancer-cell death reported for carrier-platin and defines the limits of cross-domain comparison.

• Eltanexor and XPO1: Five Questions About CRC Evidence

  2026-10-08

  A source-grounded overview of what current evidence can—and cannot—show about Eltanexor (KPT-8602) as an XPO1-directed research compound in colorectal cancer. The discussion separates findings from interpretation, explains the limits of a non-peer-reviewed preprint and mouse chemoprevention model, and places colorectal observations alongside—but not above—research contexts in hematologic malignancies.

• KG-501: CREB, KIX, and Translational Strategy

  2026-10-08

  A source-grounded perspective on KG-501 as a mechanistic probe for CREB–CBP and Myb–KIX signaling, with particular attention to macrophage biology, colitis-associated colorectal cancer, evidence strength, and translational boundaries.

• Fenipentol: Evidence, Identity, and Research Context

  2026-10-07

  Fenipentol, also called 1-Phenyl-1-pentanol, has been associated with historical hepatobiliary secretion research, but the supplied evidence contains important identity and provenance gaps. A 2024 antifibrotic study investigated the different positional isomer 1-phenyl-2-pentanol in hepatic stellate cells. This overview compares those evidence streams, explains what can and cannot be inferred, and outlines conceptual research questions without treating supplier claims as validated clinical or mechanistic conclusions.

• Amyloid β-Peptide (1-42): Evidence and Limits

  2026-10-07

  Amyloid β-Peptide (1-42), or Aβ42, is widely used to study amyloid aggregation, neuronal injury and Alzheimer’s disease mechanisms. This overview compares published evidence for ratiometric fibril imaging with supplier-reported assay claims, emphasizing what the data show, what remains uncertain and where in vitro findings should not be extrapolated.

• ABT-888 (Veliparib): A Biomarker-Aware View

  2026-10-06

  ABT-888 (Veliparib) is best understood not simply as a PARP inhibitor, but as a context-dependent probe of DNA repair and replication stress. This article connects its preclinical sensitization profile with recent evidence that PPP2R2A loss can redirect PARP-inhibitor-resistant ovarian cancer cells toward CHK1 dependence.

• Cefotaxime as a Lens on AMR Transmission

  2026-10-06

  Cefotaxime offers a useful mechanistic lens for connecting beta-lactam biology with antimicrobial resistance research. By placing the compound alongside recent evidence on carbapenemase-encoding genes in Enterobacter cloacae, this article distinguishes phenotypic activity from gene mobility, clonal spread, and clinical translation.

• Tigecycline Beyond the MIC: From Mechanism to Translation

  2026-10-05

  A translational perspective on Tigecycline that connects 30S ribosomal targeting, multidrug-resistant pathogen research, and the hospital-level resistance dynamics reported in carbapenem-resistant Enterobacter cloacae.

• Single-Cell ERK Dynamics in CRC Organoids

  2026-10-05

  Ponsioen and colleagues developed a live-cell, single-cell approach to quantify ERK signaling in patient-derived colorectal cancer organoids. Their findings show that EGFR amplifies, rather than merely initiates, oncogenic MAPK signaling in KRAS- and BRAF-mutant tumors, providing a mechanistic rationale for combining EGFR-directed treatment with downstream pathway strategies.

• Tigecycline: Evidence, Uses and Research Limits

  2026-10-04

  Tigecycline is a glycylcycline antibiotic with established clinical roles in selected complicated infections and continuing relevance to antimicrobial-resistance research. This overview compares pharmacologic rationale, clinical evidence and the 2025 Guangdong CREC study while emphasizing what the available data cannot establish about carbapenemase mobility or treatment outcomes.

• Arsenic Neurotoxicity, MMP-2/9, and BBB Injury

  2026-10-03

  A 2024 mouse study links sodium arsenite-associated learning and memory impairment with blood–brain barrier disruption, altered tight-junction proteins, MMP-2/MMP-9 elevation, and hippocampal neuronal apoptosis. Doxycycline hyclate intervention supported the proposed pathway by preserving barrier-associated findings and improving behavioral outcomes, while the pharmacological design does not establish exclusive or clinically transferable causality.

• 2'-O-Methyladenosine Assay Workflows

  2026-10-01

  Use 2'-O-Methyladenosine as a defined input for nucleoside transport, RNA modification, and purine metabolism experiments. A matrix-aware UHPLC–MS/MS workflow helps distinguish biological changes from ion suppression, isomer overlap, and sample-handling artifacts.

• AP1903: FKBP Dimerization for Cell Ablation

  2026-10-01

  AP1903 is an FKBP-binding ligand and chemical inducer of dimerization for controlled protein activation. Product data report nanomolar activity in F36V-FKBP assays, apoptosis induction in engineered HT1080 cells, and dose-dependent conditional cell ablation in mice.

• SM-164 and the Logic of Apoptotic Signal Testing

  2026-09-30

  SM-164 is a bivalent Smac mimetic that enables mechanistic analysis of IAP-dependent apoptosis. This article connects IAP antagonism with the newly defined Pol II degradation-dependent apoptotic response and shows how to separate target engagement, pathway signaling, and terminal cell-death readouts.

8492 records 1/567 page Next 12345 下5页 Last page